Topline results were announced from a phase 3 study assessing the immune response following coadministration of Arexvy and Shingrix.

NEW YORK, Sept. 20, 2024 /PRNewswire/ -- With thousands of press releases published each week, it can be difficult to keep up ...

Moderna should not be left off the list of interesting investment opportunities, as the company has one of the best pipelines ...

In Singapore’s humid climate, where respiratory illnesses can spread year-round, respiratory syncytial virus (RSV) is ...